Sarepta Therapeutics, Inc.

SRPT Healthcare Biotechnology

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

17.06 0.73 −4.10%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
4.4×
Dividend yield
—
F-score
3/9
Altman Z
−0.97
Beneish M
−3.41
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 6 4
ROE
(21.37%) (53.47%) 4.91% (9.48%)
ROA
(7.66%) (19.51%) 1.96% (3.98%)
ROIC
(5.26%) (42.46%) (1.51%) (5.64%)
Return on Tangible Assets
(12.57%) (39.90%) 3.03% (6.68%)
Average Days of Receivables
59.84 66.12 65.98 69.66
Free Cash Flow per Share
(3.88) (3.15) 1.03 0.71
Free Cash Flow
(388.84) (315.33) 108.24 74.97
Capital Expenditures
(144.20) (109.85) (67.04) (36.04)
Other line items
Cash ROIC
(12.13%) (10.84%) 3.61% 2.37%
Accounts Receivable Turnover
5.81 4.40 4.14 4.37
Accounts Payable Turnover
5.39 3.39 7.16 8.61
Inventory Turnover
0.70 1.01 0.83 0.85
Average Days of Payables
59.87 122.09 31.68 23.04
Days of Inventory on Hand
685.91 397.67 450.67 408.67
Tax Rate
0.08 0.02 1.66 0.04
Research and Development Expense of Revenue
57.86% 69.24% 41.32% 39.99%
Selling, General and Administrative Expense of Revenue
21.85% 22.37% 21.38% 22.12%
Share Based Compensation of Revenue
5.93% 5.61% 5.10% 5.00%
Operating CF/Net income
0.90 0.29 2.69 (0.81)
Depreciation/Fixed assets
0.11 0.11 0.12 0.13
Capex/Depreciation
(3.79) (2.80) (1.63) (0.86)
Revenue per Share
24.08 21.96 20.80 18.73
Operating CF per Share
(2.44) (2.05) 1.67 1.05
Capex per Share
(1.44) (1.10) (0.64) (0.34)
Capex to Sales
0.06 0.05 0.03 0.02

Fold the line items

Columns are period end dates